Tocilizumab With Steroid Taper Superior in GCA
Friday, July 28, 2017 | Medical Studies
A combination of tocilizumab plus prednisone-tapered therapy was superior to placebo plus steroid taper for achieving glucocorticoid-free remission in giant-cell arteritis (GCA), the phase 3 Giant-Cell Arteritis Actemra (GiACTA) trial shows, according to a report in Medscape.
John H. Stone, MD, from Harvard Medical School, Boston, Massachusetts, and colleagues published the results of their study in the July 27 issue of the New England Journal of Medicine.
"This trial of tocilizumab for the treatment of [GCA] showed that the two regimens of tocilizumab weekly and of tocilizumab every other week, in combination with a prednisone taper over a period of 26 weeks, were superior to placebo plus a prednisone taper of 26 weeks and to placebo plus a prednisone taper of 52 weeks with regard to sustained remission," the authors write.
You must be logged in to leave a comment.